PRION-1 aims to assess the activity and safety of Quinacrine (Mepacrine hydrochloride) in
human prion disease. It also aims to establish an appropriate framework for the clinical
assessment of therapeutic options for human prion disease that can be refined or expanded in
the future, as new agents become available.